Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages E133-E134

  Jaspers, Aurélie ^a   Baron, Frédéric ^a,b   Maertens, Johan ^c   De Prijck, Bernard ^a,d   Schots, Rik ^e   Bonnet, Christophe ^a   Hafraoui, Kaoutar ^a   Willems, Évelyne ^a   Servais, Sophie ^a,b   Fillet, Georges ^a   Beguin, Yves ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CHR de la Citadelle   (Belgium)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; FERRIC ION; IRON(III)-HYDROXIDE SUCROSE COMPLEX; SUCROSE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE NECROSIS; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; DIABETES MELLITUS; DRUG SAFETY; FOLLOW UP; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; IRON THERAPY; ISCHEMIC CARDIOMYOPATHY; LETTER; LONG TERM CARE; LYMPHOMA; METASTASIS; NEPHRITIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOPNEUMONITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOIDOSIS; SPONDYLARTHRITIS; THROMBOSIS; THYROIDITIS; TUMOR GROWTH; VASCULITIS; ANALOGS AND DERIVATIVES; ANEMIA; AUTOTRANSPLANTATION; COMPLICATION; CONTROLLED STUDY; DRUG COMBINATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; SUCROSE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84931832196     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24013     Document Type: Letter

References (6)

1. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol 2013;88:990-996.
2. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
3. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
4. Beguin Y, Aapro M, Ludwig H, et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review. Crit Rev Oncol Hematol 2014;89:1-15.
5. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
6. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012;106:1249-1258.